Study Design and Data Sources Clause Samples

Study Design and Data Sources. DialysisConnect was a pre-post pilot study conducted at Emory University Hospital Midtown (EUHM) and four Emory affiliated dialysis clinics in metropolitan Atlanta. All admissions at EUHM among Emory Dialysis patients on or after 1/1/19 and discharged before or on 5/31/21 (end of pilot) were included. EUHM electronic health record (EHR) data were used to identify all admissions and outcomes, except for post-discharge mortality, which was identified using Emory Dialysis EHR data. Patients receiving dialysis were identified in the EUHM EHR using ICD-10 diagnosis codes related to dialysis (any of: N18.6, Z99.2, Z91.1, V45.11, V45.12); in a preliminary sensitivity analysis using pre-pilot data, this method was shown to capture 99% of admissions for Emory Dialysis patients. We identified a total of 1046 index admissions among 396 individuals in the period 1/1/19-5/31/21, excluding events with discharge status of expired, left against medical advice, and planned readmissions. The study protocol and waiver of patient consent were approved by the Emory University Institutional Review Board.
View Source
Study Design and Data Sources. We conducted a retrospective analysis of a cohort created through the linkage of Georgia birth records and hospital discharge records from 1999 through 2006. Utilizing unique maternal identifiers, we were able to explore the linked vital statistics and administrative data for each mother-infant pair, as well as longitudinal records for consecutive births to the same woman (if they occurred within the identified timeframe). This technique both broadened our list of potential covariates for analysis, and validated those variables which appeared in both datasets. and second-order, live births. We then removed duplicate entries and excluded non- ▇▇▇▇▇▇▇▇▇ births, deliveries at <20 weeks gestational age, and births with missing PNC measures. Our ultimate study population included only the ▇▇▇▇▇▇▇▇▇, second-order, live births at ≥20 weeks gestational age to women whose first-order birth (if it occurred in Georgia between 1999 and 2006) was a CD, and whose birth of interest for this analysis was a VBAC or RCD.
View Source
Study Design and Data Sources. The NICHE study was a cluster-randomized, longitudinal cohort trial with the primary objectives to measure the effectiveness of Sprinkles distribution through an integrated health promotion and income-generating program, and to measure the impact of Sprinkles sales on iron deficiency and anemia among young children. The secondary objectives include: to estimate the impact of Sprinkles sales on disease morbidity such as diarrhea, fever, and cough incidence in young children. Monitoring of sprinkles sales and use, and biological impact took place in both arms of the study. Sources of monitoring data are presented in Table 3.1 and included: 1) cross- sectional baseline and follow-up surveys, including measurement of selected biomarkers and anthropometry; 2) SWAP office records of Sprinkles sales to vendors; 3) biweekly household monitoring of the selected cohort to determine Sprinkles use and health status; and 4) qualitative data collection, including focus groups and key informant interviews with vendors. Quantitative and qualitative data monitoring were integrated to increase understanding of the intervention delivery and utilization as well as confidence in the validity of the findings (83). 3.1: Sources of Monitoring Data for Sprinkles Intervention Data Source Target participants Type of research Date 3.3.1. Sample size calculation 3.3.2. Subject selection for quantitative data collection Figure 3.1 describes the selection of the cohort. Of 1420 sampled children, 1079 were enrolled, indicating an enrollment rate of 75.9%. There were no differences in enrollment rates between intervention and comparison areas. Among the 341 excluded from the study, 33.3% of children were outside of the age range (due to discrepancies in date of births reported during census), 2.9% of parents did not give consent, and 63.8% of children were unavailable for enrollment on 3 separate household visits. This resulted in an enrollment of 567 children in the intervention villages, and 512 children in the comparison villages. During the course of the study, any person found to be ill, severely anemic (hemoglobin < 7 g/dL), or febrile was referred for treatment to the nearest hospital or clinic. Figure 3.1. Selection of study subjects for the NICHE study.
View Source

Related to Study Design and Data Sources

  • Background Data The Disclosing Party's Background Data, if any, will be identified in a separate technical document.

  • Technology Upgrades Notwithstanding any other provision of this Agreement, Verizon shall have the right to deploy, upgrade, migrate and maintain its network at its discretion. The Parties acknowledge that Verizon, at its election, may deploy fiber throughout its network and that such fiber deployment may inhibit or facilitate Covista’s ability to provide service using certain technologies. Nothing in this Agreement shall limit Verizon's ability to modify its network through the incorporation of new equipment or software or otherwise. Covista shall be solely responsible for the cost and activities associated with accommodating such changes in its own network.

  • System and Data Access Services a. System. Subject to the terms and conditions of this Addendum and solely for the purpose of providing access to Fund Data as set forth herein, State Street hereby agrees to provide the Fund, or certain third parties approved by State Street that serve as the Fund`s investment advisors, investment managers or fund accountants (the "Fund Accountants") or as the Fund`s independent auditors (the "Auditor"), with access to State Street`s Multicurrency HORIZONR Accounting System and the other information systems described in Attachment A (collectively, the "System") on a remote basis solely on the computer hardware, system software and telecommunication links described in Attachment B (the "Designated Configuration") or on any designated substitute or back-up equipment configuration consented to in writing by State Street, such consent not to be unreasonably withheld.

  • Regulatory Materials (a) On a Program-by-Program basis, commencing on the Effective Date until the Regulatory Transfer Date, Prothena shall have the right, in consultation with Celgene, to prepare, file and maintain all Regulatory Materials (including any Regulatory Approvals) necessary for the Development and Manufacture of any Collaboration Candidates and Collaboration Products for such Program (collectively, the “Program Regulatory Materials”), and to interact with Regulatory Authorities in connection with the Development and Manufacture of any Collaboration Candidates and Collaboration Products for such Program. Prothena will provide Celgene with a reasonable opportunity to comment substantively on all material Regulatory Materials prior to filing or taking material action, and will reasonably and in good faith consider any comments and actions recommended by Celgene, including with respect to filing strategy. In addition, Prothena will allow Celgene or its representative to attend any and all meetings with Regulatory Authorities to the extent such attendance is not prohibited or limited by such Regulatory Authority. (b) If Celgene exercises its Phase 1 Portion Participation Right for a given Program, then immediately after such exercise, Prothena shall initiate the transfer of all Program Regulatory Materials, including for clarity any IND for the relevant Collaboration Candidates and/or Collaboration Products that are the subject of such Program to Celgene. The date on which such Program Regulatory Materials are transferred to Celgene shall be the “Regulatory Transfer Date” for such Program. Thereafter, Celgene shall have the right, in consultation with Prothena, to prepare, file, and maintain such Program Regulatory Materials, and to interact with Regulatory Authorities in connection with the Development and, as applicable, Manufacture of such Collaboration Candidates and Collaboration Products for such Program in accordance with the terms and conditions of Section 2.5. Additionally, with respect to any Phase 1 Clinical Trial conducted by Celgene pursuant to Section 2.5, Celgene will provide Prothena with a reasonable opportunity to comment substantively on all material Program Regulatory Materials prior to filing or taking material action, and will reasonably and in good faith consider any comments and actions recommended by Prothena, including with respect to filing strategy. In addition, with respect to any Phase 1 Clinical Trial conducted by Celgene pursuant to Section 2.5, Celgene will allow Prothena or its representative to attend any and all meetings with Regulatory Authorities to the extent such attendance is not prohibited or limited by such Regulatory Authority. For clarity, if the Regulatory Transfer Date does not occur prior to the expiration of the Option Term for such Program, Section 2.6.1(a) (and not this Section 2.6.1(b)) shall apply.

  • Technology Access Contractor expressly acknowledges that state funds may not be expended in connection with the purchase of an automated information system unless that system meets certain statutory requirements relating to accessibility by persons with visual impairments. Accordingly, Contractor represents and warrants to System Agency that the technology provided to System Agency for purchase (if applicable under this Contract or any related Solicitation) is capable, either by virtue of features included within the technology or because it is readily adaptable by use with other technology, of: • providing equivalent access for effective use by both visual and non-visual means; • presenting information, including prompts used for interactive communications, in formats intended for non-visual use; and • being integrated into networks for obtaining, retrieving, and disseminating information used by individuals who are not blind or visually impaired. For purposes of this Section, the phrase “equivalent access” means a substantially similar ability to communicate with or make use of the technology, either directly by features incorporated within the technology or by other reasonable means such as assistive devices or services which would constitute reasonable accommodations under the Americans With Disabilities Act or similar state or federal laws. Examples of methods by which equivalent access may be provided include, but are not limited to, keyboard alternatives to mouse commands and other means of navigating graphical displays, and customizable display appearance. In accordance with Section 2157.005 of the Texas Government Code, the Technology Access Clause contract provision remains in effect for any contract entered into before September 1, 2006.